Cardinal Health, Inc.

🇺🇸New York Stock Exchange

Articles

32
Show Summary
Show Bulletpoints
Detailed View
Somewhat Bullish +45

Cardinal Health (NYSE:CAH) Sets New 12-Month High - What's Next?

📈 Stock hit new 52-week high of $240.93 with strong volume.

💰 Q1 EPS beat estimates at $3.17 vs consensus of $2.79.

📉 Revenue missed forecasts but grew 11% year-over-year to $60.94B.

💸 Net margin low at 0.62% with negative return on equity.

🎯 FY 2026 guidance set between $10.70 and $10.80 EPS.

📈 Cardinal Health stock hit a new 52-week high of $240.93 with significant trading volume.

💰 Q1 EPS beat estimates at $3.17 versus the consensus of $2.79.

📉 Revenue missed analyst expectations, coming in at $60.94 billion against a forecast of $62.10 billion.

📈 Revenue grew 11% year-over-year to reach $60.94 billion for the quarter.

💸 Net margin was low at 0.62% with a negative return on equity of 92.61%.

🎯 FY 2026 guidance set between $10.70 and $10.80 EPS by management.

📊 Analysts expect full-year 2026 EPS of $10.76, slightly above company guidance.

💵 Quarterly dividend increased to $0.5158 per share with a yield of 0.9%.

🏦 Institutional ownership stands at 87.17% of the company's total shares.

📈 Wellington Management Group increased its stake by 153.2% in the third quarter.

🚀 Marshall Wace LLP grew its position by 1,328.1% during the fourth quarter.

🏥 Cardinal Health operates as a major provider of supply chain and distribution services for healthcare.

📦 Core business includes wholesale distribution of pharmaceuticals and medical-surgical products.

🌍 The company serves hospitals, pharmacies, physician offices, and clinical laboratories globally.

📅 Earnings data was last announced on Thursday, April 30th.

Bullish Signals
  • Stock hit new 52-week high of $240.93.
  • EPS of $3.17 beat consensus by $0.38.
  • Revenue grew 11% year-over-year to $60.94 billion.
  • Institutional ownership remains robust at 87.17%.
  • Morgan Stanley raised price target to $255.00.
Risk Factors
  • Revenue missed expectations by over $1 billion.
  • Net margin extremely low at just 0.62%.
  • Return on equity negative at -92.61%.
  • Zacks Research lowered rating from strong-buy to hold.
  • Weiss Ratings cut stock rating from buy (b+) to buy (b).
Bullish Signals
  • Stock price reached a new 52-week high of $240.93, indicating strong market momentum.
  • Reported EPS of $3.17 significantly beat the consensus estimate of $2.79 by $0.38.
  • Revenue grew 11% year-over-year to reach $60.94 billion despite missing absolute expectations.
  • Quarterly dividend increased from $0.51 to $0.5158 per share, signaling confidence in cash flow.
  • Wellington Management Group lifted its stake by 153.2%, adding over 3.5 million shares.
  • Marshall Wace LLP grew its position by 1,328.1%, acquiring nearly 900k additional shares.
  • Institutional ownership remains robust at 87.17%, indicating strong investor confidence.
  • Morgan Stanley raised its price target to $255.00 and maintained an 'overweight' rating.
Risk Factors
  • Revenue of $60.94 billion missed analyst expectations of $62.10 billion by over $1 billion.
  • Net margin was extremely low at just 0.62%, indicating potential pressure on profitability.
  • Return on equity is negative at -92.61%, suggesting significant leverage or accounting adjustments.
  • Zacks Research lowered its rating from 'strong-buy' to 'hold' in a recent report.
  • Weiss Ratings cut the stock rating from 'buy (b+)' to 'buy (b)', reflecting cautious sentiment.
Somewhat Bullish +45

Cardinal Health (CAH) Stock Could Be 7.2% Undervalued After Guidance Raise - simplywall.st

📈 Revenue rose 11% YoY with raised fiscal 2026 EPS guidance.

💰 Stock gained 16.66% in 30 days and 39.64% total return last year.

🎯 Analyst consensus target is $245.27, implying 7.2% upside from current price.

⚖️ P/E ratio of 34.3x exceeds US healthcare average of 23.2x.

⚠️ Risks include tighter regulation and potential loss of major customer contracts.

📈 Cardinal Health reported an 11% year-over-year revenue increase alongside a raise in fiscal 2026 non-GAAP EPS guidance.

💰 The stock has gained 16.66% over the past 30 days and delivered a 39.64% total shareholder return over the last year.

🎯 Analyst consensus price target is $245.27, implying a potential 7.2% upside from the recent close of $227.72.

⚖️ The company trades at a P/E ratio of 34.3x, which exceeds the US healthcare industry average of 23.2x and peer average of 25.9x.

🛡️ Analysts have identified a bullish price target of $275.00 and a bearish target of $215.00, highlighting valuation disagreement.

⚠️ Key risks include tighter regulation, increased pricing scrutiny, and the potential loss of major customer contracts.

📉 If market sentiment cools, the high P/E multiple could lead to price adjustments rather than earnings compression.

💊 Stronger demand for high-margin specialty drugs is cited as a key driver supporting recent stock momentum.

Bullish Signals
  • 11% year-over-year revenue increase.
  • Raised fiscal 2026 non-GAAP EPS guidance.
  • 39.64% one-year total shareholder return.
  • $245.27 fair value suggests discount.
  • High-margin specialty drug demand tailwind.
Risk Factors
  • P/E ratio of 34.3x exceeds industry average of 23.2x.
  • Tighter regulation threatens future revenue growth and margins.
  • Loss of major contracts impacts revenue stability.
  • Analyst price targets range from $215.00 to $275.00.
Bullish Signals
  • Cardinal Health achieved an 11% year-over-year revenue increase, demonstrating solid top-line growth.
  • The company raised its fiscal 2026 non-GAAP EPS guidance, signaling confidence in future profitability.
  • Strong price action with a 30-day return of 16.66% and a one-year total shareholder return of 39.64% indicates building momentum.
  • Analyst consensus fair value of $245.27 suggests the stock is currently trading at a discount relative to growth expectations.
  • Increased demand for high-margin specialty drugs provides a favorable tailwind for the company's core business segments.
Risk Factors
  • The current P/E ratio of 34.3x is significantly higher than the US healthcare industry average of 23.2x and peer average of 25.9x, creating valuation risk.
  • Tighter regulation and increased pricing scrutiny pose potential threats to future revenue growth and margins.
  • The loss of major customer contracts could materially impact the company's revenue stability and growth trajectory.
  • Analyst disagreement on price targets, ranging from $215.00 to $275.00, indicates uncertainty regarding the stock's long-term valuation.
Bullish +65

Quiet relief on demand, Cardinal Health Instant Cold Pack stays simple - AD HOC NEWS

🧊 Instant cold packs activate without refrigeration for single-use therapy.

🏥 Distributed via network supplying over 90% of US hospitals.

📈 Fiscal 2026 earnings guidance implies approximately 30% growth.

💰 Global market projected to reach $2.1 billion by 2033.

📉 Shares outperform sector after EPS outlook lift.

🧊 Cardinal Health's Disposable Instant Cold Pack delivers localized cold therapy within seconds of activation without requiring refrigeration.

🏥 The product is distributed through Cardinal Health's logistics network, which supplies pharmaceuticals and medical-surgical products to more than 90% of US hospitals.

📈 Cardinal Health recently raised its fiscal 2026 non-GAAP earnings guidance to a range implying approximately 30% year-on-year growth.

🔬 The pack is latex-free and shelf-stable, designed for single-use applications in emergency rooms, athletic training, and home first-aid kits.

💰 Market research projects the global hot and cold packs market will reach about $2.1 billion by 2033 from $1.3 billion in 2026.

📉 Cardinal Health shares have been outperforming the broader healthcare sector following a recent lift in its EPS outlook.

Bullish Signals
  • Raised fiscal 2026 guidance implying ~30% year-on-year growth.
  • Shares outperforming broader healthcare sector after outlook adjustment.
  • Global market projected to grow from $1.3B in 2026 to $2.1B by 2033.
  • Supplies products to over 90% of US hospitals.
Bullish Signals
  • Cardinal Health recently raised its fiscal 2026 non-GAAP earnings guidance, implying around 30% year-on-year growth driven by strength in both Pharmaceutical and Medical segments.
  • The company's shares have been outperforming the broader healthcare sector following the positive adjustment to its earnings outlook.
  • The global hot and cold packs market is projected to grow significantly from $1.3 billion in 2026 to approximately $2.1 billion by 2033 due to aging populations and sustained sports participation.
  • Cardinal Health's logistics network supplies products to over 90% of US hospitals, providing a robust distribution channel for its consumable portfolio.
Neutral 0

Evaluating Cardinal Health – Look Beyond Technicals to Fundamentals

📈 Shares rose 4.1% to $212.79, up 33.6% year-over-year.

⚠️ Current ratio of 0.91 signals insufficient liquidity for liabilities.

💰 Analysts rate it "Buy" with a target price of $245.27.

📈 Cardinal Health shares rose 4.1% in today's evening session, trading at $212.79 per share.

📊 The stock gained 33.6% over the last year, outperforming the S&P 500 by 10.9%.

🏢 Cardinal Health operates as a large-cap healthcare services and products company based in Dublin, Ohio.

👥 The company employs 53,084 full-time workers across the United States and internationally.

💰 Cardinal Health has provided a dividend yield of 1.0% over the past 12 months.

⚠️ Despite positive cash flows and leverage, the firm's current ratio is 0.91, indicating insufficient current assets to cover liabilities.

📉 Gross margins for Cardinal Health are slimmer than those of its industry peers.

📊 The trailing twelve-month P/E ratio stands at 30.9, which is higher than the sector average of 22.94.

🔮 Based on EPS guidance of $11.98, the forward P/E ratio is calculated at 16.9.

📉 A PEG ratio of 2.48 suggests that the company's shares may be overvalued relative to growth rates.

👍 Analysts maintain an average "Buy" rating with a consensus target price of $245.27 per share.

🎯 Target prices from analysts range between $215.0 and $275.0 per share.

📉 Short interest is low at 3.7% of the company's total shares outstanding.

🏛️ Institutional investors own 89.9% of Cardinal Health's shares, while insider ownership is minimal at 0.26%.

🖤 BlackRock Inc. holds the largest stake with 12% of shares worth approximately $6.06 billion.

⚠️ The analysis includes a disclaimer that past performance and data are not reliable indicators of future price movements.

📉 Market Inference does not provide financial advice or recommend buying or selling any specific security.

Bullish Signals
  • Cardinal Health gained 33.6% last year, beating S&P 500 by 10.9%.
  • Revenues and reinvestment are growing with positive EPS growth.
  • Financials show positive cash flows and healthy leverage levels.
  • Analysts target $245.27, offering upside from current price of $212.79.
  • Stock rated 'Buy' with forward P/E of 16.9 on $11.98 EPS.
Risk Factors
  • Current ratio of 0.91 indicates insufficient liquidity to cover liabilities.
Bullish Signals
  • Cardinal Health returned gains of 33.6% last year, significantly outperforming the S&P 500 index by 10.9%.
  • The company is experiencing growing revenues and increasing reinvestment in its business alongside positive EPS growth.
  • Financial statements display generally positive cash flows and healthy leverage levels.
  • Analysts have set an average target price of $245.27 per share, representing upside potential from the current trading price of $212.79.
  • The stock carries an average analyst rating of 'Buy' with a forward P/E ratio of 16.9 based on EPS guidance of $11.98.
Risk Factors
  • The company's current ratio is 0.91, meaning it does not have enough current assets to cover its current liabilities, which raises liquidity concerns.
Very Bullish +85

Here's Why You Should Add Cardinal Health Stock to Your Portfolio Now

📈 Q3 revenue grew 11% driven by strong specialty and pharmaceutical demand.

💰 Adjusted free cash flow hit $1.7B with 2026 guidance raised.

🎯 Earnings beat estimates for four consecutive quarters on average.

💼 Shares outperformed the sector, down only 2.5% as competitors fell.

🚀 Specialty revenues expanded over 20% with oncology growing more than 30%.

📈 Cardinal Health delivered strong fiscal Q3 results, driven by robust pharmaceutical distribution and accelerating specialty services.

💼 The company holds a Zacks Rank #2 (Buy) status and is positioned for continued growth via its expanding specialty portfolio.

📉 Shares have lost 2.5% year-to-date compared to the industry’s 9.3% decline, while the S&P 500 rose 8.1% in the same period.

💰 Cardinal Health has a market capitalization of $46.93 billion and projects 15.7% growth over the next five years.

🎯 Earnings have surpassed the Zacks Consensus Estimate for four consecutive quarters with an average surprise of 13.21%.

🚀 Pharmaceutical and Specialty Solutions segment revenue grew 11% in Q3 fiscal 2026, fueled by strong demand across specialty, generics, and consumer health.

⚡ Specialty revenues expanded over 20%, with oncology growing more than 30%, while management expects specialty revenues to exceed $50 billion in fiscal 2026.

🌐 At-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics saw revenues surge 31% to $1.7 billion in the fiscal third quarter.

🩺 Theranostics growth exceeded 30%, while Advanced Diabetes Supply added nearly 500,000 patients through continued integration progress.

💵 The company generated $1.7 billion in adjusted free cash flow in the third quarter and raised fiscal 2026 guidance to $3.3-$3.7 billion.

🔄 Cardinal Health repurchased $1 billion worth of shares year-to-date, reducing leverage to 3.0x within its target range.

📉 The Inflation Reduction Act (IRA) pricing adjustments reduced reported revenue growth by approximately 6 percentage points in the fiscal third quarter.

🏭 Global Medical Products and Distribution (“GMPD”) segment revenues were flat year-over-year due to tariff-related headwinds and lower distribution volumes.

🛠️ Management continues to invest in automation, technology upgrades, and supply-chain improvements to maintain record-high service levels.

📊 The Zacks Consensus Estimate for 2026 EPS improved 3.9% over the past 30 days to $10.72.

Bullish Signals
  • fiscal Q3 revenue growth in Pharmaceutical & Specialty: +11%, specialty +20%.
  • Oncology growth >30%; theranostics grew >30% in NPHS businesses.
  • Generated $1.7B adjusted free cash flow; raised 2026 FCF guidance to $3.3-3.7B.
  • Repurchased $1B shares YTD; reduced leverage to 3.0x within target range.
  • Earnings exceeded Zacks consensus for 4 quarters with +13.21% average surprise.
  • Shares down only 2.5% vs industry's 9.3% decline this year.
  • Specialty revenues projected >$50B in fiscal 2026 via expansion and Solaris integration.
  • EPS estimate improved 3.9% to $10.72 over past 30 days.
Bullish Signals
  • Cardinal Health delivered strong fiscal third-quarter results with revenue growth in its Pharmaceutical and Specialty Solutions segment of 11%, including specialty revenues growing over 20%.
  • Oncology growth within the pharmaceutical segment expanded by more than 30%, while theranostics grew by over 30% in other businesses like Nuclear and Precision Health Solutions (NPHS).
  • The company generated $1.7 billion in adjusted free cash flow during the third quarter and has raised its fiscal 2026 free cash flow guidance to $3.3-$3.7 billion.
  • Cardinal Health repurchased $1 billion worth of shares year to date, exceeding its baseline target while reducing leverage to 3.0x, which is comfortably within its target range.
  • Management increased fiscal 2026 free cash flow guidance to $3.3-$3.7 billion, reflecting confidence in future performance and continued improvement in the business.
  • Earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 13.21%.
  • The company's shares have lost only 2.5% so far this year compared to the industry's 9.3% decline, demonstrating relative strength in a challenging environment.
  • Specialty revenues are expected to exceed $50 billion in fiscal 2026, supported by MSO expansion, biopharma solutions, and the Solaris integration.
  • The Zacks Consensus Estimate for earnings per share (EPS) has improved 3.9% to $10.72 over the past 30 days, indicating an improving estimate revision trend.
Risk Factors
  • Cardinal Health's shares have lost 2.5% year-to-date, significantly underperforming the S&P 500 which increased 8.1% during the same period.
  • The Global Medical Products and Distribution (GMPD) segment revenues remained flat year over year while profit declined to $25 million due to tariff-related headwinds and lower distribution volumes.
  • Inflation Reduction Act (IRA)-related WAC pricing adjustments reduced revenue growth by approximately 6 percentage points in the fiscal third quarter, offsetting positive GLP-1 contributions.
  • GMPD profitability remains vulnerable to external pressures such as tariffs, fuel costs, and commodity inflation, which could delay margin recovery in this segment.
  • Lower branded drug prices can suppress reported top-line growth due to IRA pricing changes, even if contract economics remain protected through fee renegotiations.
  • The shift from branded drugs to generics following loss-of-exclusivity events can limit revenue visibility despite being favorable for profitability.
Bullish +75

Is CAH Becoming the Backbone of US Healthcare Infrastructure?

💊 Cardinal Health generated $61B quarterly revenue with strong U.S. manufacturing reliability.

🚀 CAH shares dropped only 2.8% this year versus the industry's 10.3% decline.

🤖 Hims & Hers serves 2.6M subscribers via an AI-enabled consumer-first platform.

🏥 LifeMD integrates telehealth, pharmacy, and diagnostics into a unified virtual care ecosystem.

📈 Zacks ranks CAH as a Buy with estimated 2026 earnings up 30.1%.

🏥 Cardinal Health is positioning itself as a foundational layer of the U.S. healthcare system by leveraging scale and operational reliability.

💊 The company's Pharmaceutical & Specialty Solutions segment contributed approximately $61 billion to quarterly revenues.

🌐 Cardinal Health's influence spans multiple layers including specialty drug distribution, MSO platforms, biopharma services, and nuclear medicine.

🤝 Specialty Alliance networks in oncology, rheumatology, and urology deepen provider relationships with the company.

🏭 The majority of Cardinal Health's manufacturing facilities are based in the United States to reinforce supply chain reliability.

🔄 Cardinal Health is driving integration across healthcare supply chains through its "specialty flywheel" strategy connecting manufacturers, providers, and patients.

📉 CAH shares have lost 2.8% so far this year compared with the industry's 10.3% decline.

📊 Cardinal Health trades at a forward price-to-earnings ratio of 16.93, which is above the industry average.

🚀 The Zacks Consensus Estimate for fiscal 2026 earnings implies a 30.1% rise from the year-ago period's level.

📈 The stock currently carries a Zacks Rank #2 (Buy).

🤖 Hims & Hers Health is reshaping infrastructure by building a consumer-first, technology-enabled care platform bypassing traditional friction points.

👥 Hims & Hers now supports nearly 2.6 million subscribers and tens of millions of annual patient touchpoints using AI.

🏥 LifeMD is redefining healthcare infrastructure by creating an integrated virtual care ecosystem combining telehealth, pharmacy, diagnostics, and insurance integration.

🤖 LifeMD uses AI to improve provider productivity and personalize treatment across weight management and chronic care.

📜 This article originally published on Zacks Investment Research (zacks.com).

Bullish Signals
  • Cardinal Health evolves into critical healthcare infrastructure partner leveraging scale.
  • $61B quarterly revenue from Pharmaceutical & Specialty Solutions segment.
  • Expanded into specialty drug distribution and precision health solutions.
  • Maintains service continuity during supply-chain disruptions with US manufacturing.
  • Specialty flywheel strategy connects manufacturers, providers, and patients.
  • Shares lost only 2.8% vs industry's 10.3% decline.
  • Fiscal 2026 earnings imply 30.1% rise from year-ago level.
  • Value Score A with forward P/E of 16.93.
Risk Factors
  • Shares underperformed healthcare sector with only 2.8% drop vs 10.3% industry decline.
  • Forward P/E of 16.93 exceeds industry average and five-year median of 13.67.
  • High valuation contradicts A Value Score suggesting potential overvaluation relative to peers.
Bullish Signals
  • Cardinal Health is evolving from a distributor into a critical healthcare infrastructure partner, leveraging scale and operational reliability to deepen its role across pharmaceutical distribution, specialty care, and advanced logistics.
  • The company's Pharmaceutical & Specialty Solutions segment contributed approximately $61 billion to quarterly revenues, underscoring the massive scale and centrality of its operations to healthcare delivery.
  • Cardinal Health has expanded into high-value areas including specialty drug distribution, physician-facing MSO platforms, biopharma services, logistics, nuclear medicine, and precision health solutions.
  • Management emphasizes Cardinal Health's ability to maintain service continuity during industry-wide supply-chain disruptions and drug shortages, with the majority of its manufacturing facilities based in the United States.
  • The company's 'specialty flywheel' strategy connects manufacturers, providers, and patients through a unified ecosystem, enhancing visibility, improving efficiency, and creating cross-segment growth opportunities.
  • Shares of CAH have lost only 2.8% so far this year compared with the industry's 10.3% decline, demonstrating relative outperformance during market downturns.
  • The Zacks Consensus Estimate for Cardinal Health's fiscal 2026 earnings implies a 30.1% rise from the year-ago period's level, signaling strong growth expectations.
  • Cardinal Health carries a Value Score of A and trades at a forward price-to-earnings ratio of 16.93, which is above the industry average but supported by its strategic positioning.
Risk Factors
  • Shares of Cardinal Health (CAH) have underperformed the broader healthcare industry this year, declining only 2.8% compared to the industry's 10.3% drop.
  • The stock trades at a forward price-to-earnings ratio of 16.93, which is significantly above both the industry average and its own five-year median of 13.67.
  • Despite the high valuation, CAH carries a Value Score of A, suggesting potential overvaluation relative to peers.
Neutral +6

Cardinal Health Inc. stock (US14149Y1082): dividend hike and higher FY2026 guidance in focus - AD HOC NEWS

📈 Cardinal Health raised its 2026 earnings guidance to $10.70–$10.80 EPS.

💰 Dividend increases 29 consecutive years; annualized payout is now ~$2.04/share.

🏥 Business relies on high-volume drug distribution and growing specialty therapeutics.

📈 Cardinal Health raised its quarterly dividend and lifted fiscal 2026 earnings guidance to signal confidence in its business momentum.

💰 The most recent dividend adjustment added approximately $0.0051 per share, extending the company's streak of annual increases to 29 consecutive years.

📊 Management now projects non-GAAP earnings per share for fiscal 2026 in a range of roughly $10.70 to $10.80, representing a significant upward revision.

🏥 Cardinal Health operates as one of the largest healthcare distributors in the US, supplying prescription drugs, OTC medicines, and medical products to hospitals and pharmacies.

💊 The company’s revenue model relies on high volumes of branded and generic pharmaceuticals with additional contributions from specialty drug services and medical products.

🦠 Specialty distribution, particularly in oncology and complex therapies, has become an increasingly important growth driver as advanced treatments take a larger share of drug spending.

🔬 Beyond pharmaceuticals, Cardinal Health generates meaningful revenue from medical and surgical products such as gloves, gowns, needles, and lab equipment used in hospitals.

📦 The firm has invested in value-added services like inventory management and analytics to deepen customer relationships and support margins despite competitive pricing pressures.

💵 As of early April 2026, Cardinal Health pays an annualized dividend of about $2.04 per share, corresponding to a yield of roughly 1.05%.

📉 The dividend payout ratio stands at approximately 31% of trailing earnings and around 17-19% based on current and next-year earnings estimates.

⏳ Over the past five years, Cardinal Health’s dividend has grown by about 1.02% per year on average, reflecting a cautious approach to increasing payouts.

📈 The updated fiscal 2026 guidance indicates stronger than previously expected earnings momentum driven by both distribution and specialty segments.

💼 Analysts and investors are closely monitoring how the updated outlook shapes the stock’s medium-term profile and validates management's strategic priorities.

Bullish Signals
  • Cardinal Health Inc. raised dividend and lifted fiscal 2026 guidance.
  • Company extends impressive streak of raising dividends for 29 consecutive years.
  • Management raised non-GAAP EPS guidance range to $10.70-$10.80 for FY2026.
  • Conservative payout ratio of roughly 31% ensures high dividend growth safety.
  • Specialty pharma distribution remains a key driver with rising advanced demand.
Risk Factors
  • Low margins make earnings sensitive to volume or pricing shifts.
  • Revenue depends heavily on large, competitive customer contracts.
  • Medical segment vulnerable to hospital spending and supply chain trends.
  • Limited upside with non-GAAP EPS projection between $10.70-$10.80.
  • Low dividend growth of ~1.02% annually lags investor expectations.
  • High retention rates limit immediate yield appeal despite increases.
  • Focus on specialty pharma exposes company to higher therapy risks.
Bullish Signals
  • Cardinal Health Inc. announced a quarterly dividend increase and lifted its fiscal 2026 earnings guidance, signaling strong confidence in its specialty pharmaceutical and distribution franchises.
  • The company extended its impressive streak of raising dividends for 29 consecutive years as of early April 2026, reinforcing its status as a reliable income investment for shareholders.
  • Management raised its non-GAAP earnings per share guidance for fiscal 2026 to a range of $10.70 to $10.80, representing a positive midpoint increase of approximately $0.50 compared to previous targets.
  • Cardinal Health maintains a conservative dividend payout ratio of roughly 31% based on trailing earnings and an even lower multiple of 17% to 19% against current and next-year estimates, providing high safety for dividend growth.
  • The company's specialty pharmaceutical distribution segment, including oncology and complex therapies, continues to serve as a key growth driver supported by rising demand for advanced treatments.
  • Management's recent investments in value-added services like inventory management and analytics are positioned to deepen customer relationships and potentially support margin expansion.
Risk Factors
  • Cardinal Health operates on a business model characterized by high volumes and relatively low margins, making earnings highly sensitive to even small shifts in volume or pricing.
  • Revenue depends heavily on the flow of branded and generic pharmaceuticals, meaning individual customer contracts are large and inherently competitive.
  • The medical segment performance is vulnerable to fluctuations in hospital spending trends, procedure volumes, and supply-chain dynamics as providers adjust inventories.
  • While management raised guidance for fiscal 2026, non-GAAP earnings per share projections range only between $10.70 and $10.80, indicating limited upside potential from this revision.
  • The company's average dividend growth over the past five years is low at approximately 1.02% annually, reflecting a cautious approach that may lag investor expectations for capital returns.
  • A significant portion of earnings (roughly 69%) and operating cash flow (around 81-83%) are retained rather than paid out as dividends, which limits immediate yield appeal despite the streak of increases.
  • Specialty pharmaceutical distribution is becoming increasingly important for growth, but this focus exposes the company to higher risks associated with high-value therapies and shifting drug spending patterns.
Neutral 0

Cardinal Health Was Supposed to Beat UnitedHealth. Did It? Will It?

📉 UnitedHealth recently outperformed Cardinal Health with 35.2% returns vs 21.8%.

⚠️ Cardinal Health faces short-term momentum issues despite a revised upside target.

💡 Investment choice now hinges on investor profile, balancing growth versus dividends.

📉 The original recommendation favoring Cardinal Health over UnitedHealth was proven incorrect as UnitedHealth significantly outperformed Cardinal in the trailing 12 months.

💰 UnitedHealth returned 35.2% between May 2025 and May 2026, while Cardinal Health returned 21.8% during the same period.

📊 UnitedHealth's strong recent performance was driven by a Q1 2026 EPS beat of $7.23 versus the $6.61 consensus estimate.

⚖️ Cardinal Health delivered a Q3 FY26 non-GAAP EPS beat but suffered from a revenue miss and a significant goodwill impairment charge.

📉 Short-term momentum has shifted against Cardinal, which is down 10.7% over the past month despite missing on key growth metrics.

💡 Analyst consensus for UnitedHealth suggests less upside potential at $387.27 compared to its current share price, reflecting a completed rebound.

🔼 Analyst sentiment favors Cardinal Health with a Wall Street target of $245.27 and an 88% bullish rating distribution from coverage.

📈 Cardinal Health has raised its full-year 2026 EPS guidance to between $10.70 and $10.80, representing 30% to 31% growth.

🧘‍♂️ UnitedHealth's turnaround under CEO Stephen Hemsley has been validated by improved medical cost ratios and stronger operational metrics.

⚠️ Long-term concerns persist for UnitedHealth regarding a DOJ probe and a decline in Medicare Advantage membership of 965,000 members.

🛡️ Cardinal Health offers higher beta with lower volatility (0.54), making it potentially attractive for investors seeking near-term drawdown tolerance.

💵 UnitedHealth generated substantial dividend income by paying $2.0 billion in Q1 2026 alone, appealing to retirement-focused investors.

🎯 Risk-adjusted analysis currently favors Cardinal Health due to wider implied upside and faster growth guidance despite UnitedHealth's strong recent rally.

🔄 The article concludes that the investment decision now splits based on investor profile, with UnitedHealth suited for scale and dividends.

Bullish Signals
  • Cardinal Health delivered strong total returns of 21.8%.
  • Q3 FY26 EPS beat guidance with 30-31% growth raised.
  • Wall Street consensus target implies material upside at $245.27.
  • 88% bullish coverage with no Sells and three Strong Buys.
  • Beta of 0.54 offers lower volatility than peers.
Risk Factors
  • Stock price doubled since May, leaving little upside.
  • Overhangs include DOJ Medicare actions and 965k membership drop.
  • Rally consumed value cushion for waiting investors.
  • Q1 FY2026 EPS beat $7.23 limits future upside.
  • Cardinal Health income fell 30.27% with $184m impairment.
Bullish Signals
  • Cardinal Health delivered strong total returns of 21.8% over the past year, growing from $153.00 to $186.35.
  • Following a Q3 FY26 non-GAAP EPS beat of $3.17 against estimates of $2.79, management has raised full-year guidance to reflect 30% to 31% growth in non-GAAP EPS.
  • The Wall Street consensus price target of $245.27 implies material upside for the stock.
  • Analyst sentiment remains robust with 88% bullish coverage, consisting of three Strong Buy ratings and twelve Buy ratings versus zero Sells.
  • With a beta of 0.54, Cardinal Health offers lower volatility compared to peers while maintaining exposure to healthcare growth.
  • The stock is currently trading below the analyst consensus target, providing room for price appreciation toward $231.18 according to 24/7 Factor targets.
Risk Factors
  • UnitedHealth Group's stock price has nearly doubled since May 29, 2025, leaving very little room for further appreciation as the current share price is already above Wall Street consensus targets.
  • UnitedHealth faces significant overhangs from ongoing Department of Justice Medicare actions and a recent decline in its Medicare Advantage membership of 965,000 members.
  • The stock has rallied significantly, eating up much of the cushion for investors who were previously buying on value or waiting for a better entry point.
  • UnitedHealth's Q1 FY2026 adjusted EPS of $7.23 beat consensus estimates, which is often interpreted by markets as limited upside potential once strong results are priced in.
  • Cardinal Health recently reported a 30.27% year-over-year operating income decline and took an $184 million goodwill impairment related to Navista and ION.
Somewhat Bullish +50

Cardinal Health, Inc. (CAH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

💼 Executives presented at BofA conference on May 13, 2026.

✅ Q3 earnings showed strong performance across the enterprise.

📈 Pharma segment profits grew 18%, while others exceeded 30%.

🚀 Management remains confident in executing their GMPD improvement plan.

📅 Cardinal Health presented at the Bank of America Global Healthcare Conference on May 13, 2026.

💼 The company's executive team includes CFO Aaron Alt and VP of Investor Relations Dave Frost.

⚠️ Management issued standard forward-looking statements subject to risks detailed in SEC filings.

✅ The company recently released Q3 earnings results that they consider strong across the enterprise.

📈 Pharma business segment delivered 18% profit growth in the third quarter.

🧬 The "other" category, consisting of three specific growth businesses, saw profit growth exceeding 30%.

🚀 Management expressed confidence in executing their GMPD improvement plan to drive overall performance.

Bullish Signals
  • Pharma profit grew 18%.
  • '3 growth businesses' profits rose over 30%.
  • Management reaffirmed strong GMPD execution.
Risk Factors
  • No specific quantitative risks or downside catalysts disclosed.
  • Lack of negative commentary despite recent strong earnings.
Bullish Signals
  • Cardinal Health's Pharma business delivered a strong 18% profit growth, demonstrating robust performance in their core pharmaceutical segment.
  • Their other business units, specifically referred to as the '3 growth businesses', achieved an impressive over 30% profit increase, indicating significant upside potential.
  • Management reaffirmed strong execution of their GMPD (Global Medicine & Patient Data) improvement plan, which is critical for driving overall enterprise growth.
Risk Factors
  • Management provided only a general reference to SEC filings for forward-looking statements, without specifying any specific quantitative risks or downside catalysts in this transcript.
  • The company noted that earnings were released just days prior and that they 'feel really good,' which may indicate the absence of negative commentary typically included when significant headwinds are present.
Somewhat Bullish +50

Cardinal Health stock (US14149Y1082): JPMorgan raises price target to $215 - AD HOC NEWS

📉 JPMorgan raised its price target to $215 despite a 7.8% same-day stock drop.

💊 Cardinal Health ranks second in US pharma distribution with massive FY2025 revenue.

🏛️ The company generates over 75% of income from pharmaceuticals and holds a 20% market share.

📈 JPMorgan Chase raised its price target for Cardinal Health (CAH) shares to $215 per share on May 11, 2026.

📉 Despite the analyst upgrade, the stock experienced a 7.8% decline in trading on that same date.

🏆 Zacks Investment Research maintains a "Buy" recommendation (Rank #2) and an "A" grade for value on Cardinal Health.

💊 Cardinal Health operates as the second-largest distributor of pharmaceuticals and medical products in the US, trailing only McKesson by revenue.

📦 In fiscal year 2025, the company reported total revenue of $226.8 billion through its Pharmaceutical and Medical segments.

💉 The Pharmaceutical segment contributes over 75% of revenue, focusing on brand-name drugs, generics, and opioids managed via OptumRx.

🩺 The Medical segment generates income from devices, apparel, surgical kits, gloves, gowns, and at-home patient solutions.

📊 Cardinal Health holds approximately 20% market share in US drug distribution, providing stability amid rising demand for pharmaceuticals.

📉 The company faces margin pressure from drug pricing reforms but expects growth driven by high volume and specialty pharma trends.

👵 Business alignment with aging demographics supports long-term relevance through specialty pharma and home infusion services.

🇺🇸 With over 90% of revenue originating from North America, the stock serves as a proxy for US healthcare spending, projected at $4.9 trillion in 2026.

🏢 Cardinal Health competes in a consolidating sector involving pharmacy benefit managers and hospital systems.

🚫 This article does not constitute investment advice, noting that stocks are volatile financial instruments.

Bullish Signals
  • JPMorgan raises price target to $215.
  • Zacks awards 'Buy' rating with 'A' value grade.
  • Record revenue reaches $226.8 billion for FY 2025.
  • Dominant #2 US position with 20% drug market share.
  • Sustained post-pandemic demand boosts medical segment revenue.
  • US healthcare spending projected to hit $4.9 trillion in 2026.
  • Focus on specialty pharma supports aging population trends.
Risk Factors
  • Cardinal Health stock fell 7.8% on May 11, 2026.
  • US medical sector faces margin compression from drug pricing reforms.
  • 90%+ revenue reliance exposes company to domestic economic risks.
Bullish Signals
  • JPMorgan Chase & Co. raised its price target for Cardinal Health to $215, indicating strong analyst confidence in the stock's value.
  • Zacks awarded Cardinal Health a 'Buy' rating with Rank #2 and a Value grade of 'A', highlighting its financial strength.
  • The company reported record-breaking total revenue of $226.8 billion for the fiscal year ended June 30, 2025.
  • Cardinal Health holds a dominant #2 position in the US medical distribution sector with over 20% market share in drug distribution.
  • Revenue from the Medical segment is being boosted by sustained post-pandemic demand for products like gloves, gowns, and surgical kits.
  • US healthcare spending is projected to reach $4.9 trillion in 2026, providing a stable foundation for Cardinal Health's growth.
  • The company aligns well with demographic trends as its focus on specialty pharma and home infusion supports an aging US population.
Risk Factors
  • Cardinal Health stock declined by 7.8% during the trading session on May 11, 2026, despite a concurrent analyst price target raise.
  • The company operates in the US medical distribution sector which faces margin compression due to ongoing drug pricing reforms.
  • With only 90%+ of revenue coming from North America, Cardinal Health remains highly exposed to domestic economic health and local pharmacy benefit manager trends.
Bullish +60

Should Value Investors Buy Cardinal Health (CAH) Stock? - Yahoo Finance

📈 Cardinal Health holds a Zacks Rank #2 with an A-grade Value score.

💰 Its PEG ratio of 1.24 is significantly lower than the industry average.

💸 The stock's P/CF ratio remains competitively valued relative to peers.

🏥 Cooper Companies also shows strong value metrics including a low P/B ratio.

⚠️ Both firms offer attractive earnings outlooks for strategic value investors.

📈 Cardinal Health (CAH) holds a Zacks Rank #2 (Buy) and an A-grade in the Value category according to the Style Scores system.

💰 CAH has a PEG ratio of 1.24, which is significantly lower than its industry average of 1.76, suggesting potential undervaluation relative to earnings growth.

💸 The stock's Price-to-Cash-Flow (P/CF) ratio stands at 15.27, compared to an industry average of 15.38, indicating it is competitively valued based on cash flow metrics.

🏥 For comparison, The Cooper Companies (COO) also carries a Zacks Rank #2 and an A-grade Value score in the medical supplies sector.

📊 COO's Forward P/E ratio of 15.59 is slightly below its industry average of 15.32, while its PEG ratio of 1.67 mirrors the market norm of 1.76.

📉 The Cooper Companies' P/B ratio of 1.62 is notably lower than the industry average of 4.56, highlighting a potentially undervalued asset base.

📈 Analysts suggest both CAH and COO represent strong value stocks currently given their impressive earnings outlooks and favorable valuation metrics.

💡 Value investors typically look for specific traits like high Zacks Rank grades combined with A-level Value scores to identify great companies.

🛑 While PEG ratios have fluctuated over the last 12 months, CAH's median of 1.49 remains below the industry average, supporting a buy rating.

⚠️ Investors are advised to consider both earnings estimates and individual strategies when deciding whether to purchase these value-oriented stocks.

Bullish Signals
  • Cardinal Health (CAH) holds Zacks Rank #2 Buy.
  • Stock earns 'A' grade in the Value category.
  • PEG ratio of 1.24 is below industry average.
  • P/CF ratio of 15.27 signals strong cash flow.
Risk Factors
  • No mentioned downside risks for Cardinal Health (CAH).
  • Text lacks competitive threat analysis.
  • Implies zero negative sentiment in financial outlook.
Bullish Signals
  • Cardinal Health (CAH) holds a Zacks Rank #2 (Buy), indicating strong potential based on earnings estimates and revisions.
  • The stock also carries an 'A' grade in the Value category, positioning it as one of the strongest value stocks on the market today.
  • CAH has a PEG ratio of 1.24, which is significantly lower than its industry average of 1.76, suggesting attractive earnings growth relative to price.
  • The company's P/CF ratio stands at 15.27, which is more attractive than the industry average of 15.38 and signals strong cash flow.
  • Over the past 52 weeks, CAH's PEG ratio ranged from a low of 1.22 to a median of 1.49, demonstrating consistent value metrics compared to its sector.
Risk Factors
  • The article presents Cardinal Health (CAH) as a strong value stock with a 'Buy' Zacks Rank and an 'A' grade, lacking any mention of potential downside risks or competitive threats.
  • Analysts are suggesting that CAH is currently undervalued, which implies there is little to no negative sentiment regarding its current financial outlook within the text.
Somewhat Bullish +50

5 Best Fortune 500 Stocks to Buy According to Analysts

📈 TD Cowen upgrades CAH price target to $255 with 30% upside.

💰 Q3 adjusted EPS of $3.17 beat estimates by $0.38.

📉 Revenue fell short of expectations due to sector slowdowns.

💊 Pharma revenue slowed from Inflation Reduction Act impacts.

🏥 Cardinal Health (CAH) is a Fortune 500 company operating as a global distributor of pharmaceuticals, medical products, and laboratory solutions.

📈 TD Cowen upgraded its price target on CAH from $251 to $255 while maintaining a "Buy" rating, indicating a 30% upside.

💰 The analyst's move follows the company's Q3 report where adjusted earnings of $3.17 per share significantly beat estimates by $0.38.

📉 Despite strong earnings, CAH's revenue of nearly $61 billion fell short of expectations due to growth in other sectors.

💊 Pharmaceutical revenue specifically slowed due to Inflation Reduction Act changes impacting wholesale acquisition costs.

🎯 Cardinal Health raised its full-year 2026 adjusted EPS target to between $10.70 and $10.80, surpassing analyst consensus.

⚙️ Analysts updated their models based on the quarterly results to reflect the new operational realities for the healthcare giant.

Bullish Signals
  • TD Cowen raised Cardinal Health target to $255 on May 1.
  • New target implies 30% upside from current price levels.
  • Earnings beat estimates by $0.38 at $3.17 per share.
  • Revenue grew 11% year-over-year despite missing revenue expectations.
  • Management raised full-year 2026 EPS target to $10.70-$10.80.
  • Guidance raised above analyst consensus and previous forecast.
Risk Factors
  • Revenue missed expectations by $1.3 billion.
  • Pharma growth hit by Inflation Reduction Act.
  • Strong earnings mask core business weakness.
Bullish Signals
  • On May 1, TD Cowen raised its price target on Cardinal Health from $251 to $255 while maintaining a 'Buy' rating.
  • The new target implies an upside of 30% from current price levels for the stock.
  • Cardinal Health reported Q3 adjusted earnings of $3.17 per share, beating analyst estimates by $0.38.
  • Despite missing revenue expectations, Cardinal Health achieved year-over-year revenue growth of 11%.
  • Management demonstrated confidence by raising its full-year 2026 adjusted EPS target to $10.70-$10.80 per share.
  • The company raised its guidance above both its previous forecast and the analyst consensus estimate.
Risk Factors
  • Cardinal Health's revenue of almost $61 billion fell short of expectations by $1.3 billion, indicating a significant miss in top-line performance despite year-over-year growth.
  • The company's Pharmaceutical revenue growth was explicitly hurt by changes related to the Inflation Reduction Act impacting wholesale acquisition costs of drugs.
  • Despite reporting strong Q3 earnings, the substantial revenue miss suggests potential underlying weakness in its core business operations or market demand.
Slightly Bullish +25

Cardinal (CAH) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

📉 CAH dropped 8.8% but formed a bullish hammer pattern signaling exhaustion.

💡 Rising EPS estimates and a Zacks Rank #2 support near-term price appreciation.

🔄 Fundamental optimism and technical signals combine to suggest a potential trend reversal.

📉 Cardinal Health (CAH) recently lost 8.8% over two weeks but may be nearing a bottom after forming a hammer chart pattern.

🕯️ The hammer pattern indicates selling pressure exhaustion, characterized by a small body and a long lower wick that is at least twice the length of the body.

💡 This technical formation suggests bulls are counteracting bears, signaling potential loss of bearish control over the stock price.

📈 Fundamental optimism is driving analyst expectations, evidenced by a 4.4% increase in consensus EPS estimates for the current year over the last 30 days.

🔄 An upward trend in earnings estimate revisions typically translates into near-term price appreciation for CAH.

🥈 The stock currently holds a Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 stocks ranked by earnings trends and surprises.

🚀 Stocks with a Zacks Rank #1 or #2 have historically shown the ability to outperform the broader market.

⏱️ The Zacks Rank serves as an effective timing indicator that helps pinpoint when a company's future prospects are improving.

🛠️ Investors are advised to use the hammer pattern alongside other bullish indicators, as it has limitations and depends on chart placement.

📊 Cardinal Health operates as a major prescription drug distributor facing a potential trend reversal based on combined technical and fundamental factors.

Bullish Signals
  • Hammer pattern after an 8.8% decline signals reversal.
  • Rising analyst optimism provides solid fundamental support.
  • Consensus EPS estimate increased 4.4% in 30 days.
  • Cardinal Health holds a Zacks Rank #2 Buy.
  • Rank #1/2 stocks historically outperform the market.
Risk Factors
  • Stock lost 8.8% in two weeks showing bearish sentiment.
  • Cardinal Health shows a persistent downtrend indicating weakness.
  • Hammer patterns need confirmation as a standalone indicator.
  • Zacks Rank #2 Buy falls short of top-tier #1.
Bullish Signals
  • A hammer chart pattern was formed in Cardinal Health's last trading session, signaling a potential trend reversal after a recent 8.8% decline.
  • Rising optimism among Wall Street analysts regarding future earnings is providing a solid fundamental factor to support the stock.
  • The consensus EPS estimate for the current year has increased by 4.4% over the last 30 days, indicating improving analyst expectations.
  • Cardinal Health currently holds a Zacks Rank #2 (Buy), placing it in the top 20% of more than 4,000 stocks based on earnings trends and surprises.
  • Historically, stocks with a Zacks Rank #1 or #2 have outperformed the market, suggesting a strong potential for upside.
Risk Factors
  • The stock has lost 8.8% over the past two weeks, indicating recent significant selling pressure and bearish sentiment.
  • A downtrend has been apparent in Cardinal Health lately, suggesting ongoing weakness despite any potential technical reversal signals.
  • Hammer chart patterns have limitations as a standalone indicator; they require confirmation from other bullish indicators to be reliable.
  • While currently holding a Zacks Rank #2 (Buy), the stock is not ranked #1 (Strong Buy), which suggests it may not be in the very top tier of performing stocks.
Somewhat Bullish +27

We're adding to our position in a stock that has gotten cheaper since earnings

🚀 Jim Cramer's Trust bought more Cardinal Health shares after a dip.

💰 Valuation is attractive at 16.5x estimates versus a March high of 20x.

📈 Analysts raised 2027 EPS estimates and expect long-term teens growth.

🚀 Jim Cramer's Charitable Trust increased its holding in Cardinal Health (CAH) by purchasing 50 additional shares at approximately $199.

📉 The trade capitalizes on a post-earnings decline, though the report initially showed a revenue miss and $184 million in impairment charges for specific reporting units.

📈 Analyst confidence remains high, with many raising their fiscal year 2027 earnings per share estimates to $11.91 from about $11.60 prior to the release.

💰 The stock's valuation has become attractive, trading at roughly 16.5 times next twelve months' estimates compared to a high of around 20 times in early March.

🤝 Management and the analyst community maintain confidence in Cardinal Health's ability to grow earnings per share in the low-to-mid teens over the long term.

📊 Following this purchase, the trust's total holding increased to 525 shares, representing a portfolio weight of 2.75% up from 2.50%.

⏳ Trading for CNIBC subscribers follows specific rules, such as waiting 45 minutes after sending an alert or 72 hours if the stock was discussed on CNBC TV.

📝 The article includes standard disclaimers stating that information is subject to terms and conditions, with no fiduciary obligation or guaranteed outcomes.

Bullish Signals
  • Charitable Trust adds shares in Cardinal Health (CAH) at $199.
  • Analysts raise FY2027 EPS estimate to $11.91 on FactSet.
  • Stock trades at ~16.5x earnings, down from ~20x in March.
  • Consensus estimates rise despite recent revenue miss.
Risk Factors
  • Missed fiscal 2026 Q3 revenue expectations.
  • $184M impairment charges hurt profitability.
  • Stock declined post-earnings announcement.
Bullish Signals
  • The Charitable Trust is adding shares to its position in Cardinal Health (CAH) following a post-earnings price decline, increasing its holding to 525 shares at an attractive entry point of roughly $199.
  • Both management and the analyst community express confidence in Cardinal Health's ability to grow earnings per share in the low-to-mid teens over the long term, prompting many analysts to raise their fiscal year 2027 EPS estimate from $11.60 to $11.91 on FactSet.
  • The stock is trading at a mid-teens price-to-earnings multiple of roughly 16.5 times next 12 months estimates, which represents a significant discount compared to the approximately 20x earnings multiple seen in early March.
  • Analysts have raised their consensus earnings estimate for fiscal year 2027 despite a recent revenue miss and impairment charges, indicating strong upside potential in future growth projections.
Risk Factors
  • Cardinal Health missed revenue expectations in its fiscal 2026 third quarter report.
  • The company recorded $184 million in impairment charges specifically for its Navista and ION reporting units, impacting overall profitability.
  • Shares recently experienced a price decline following the earnings announcement, indicating short-term negative market sentiment.
Bullish +75

Cardinal Health's sell-off on earnings was an overreaction. We'd be buyers

📉 Stock dropped 4.9% after missing top-line expectations and recording an $184M impairment charge.

⏱️ CEO confirms strategy remains unchanged despite recent financial setbacks and trading restrictions.

👵 Long-term growth relies on an aging population and expansion into specialty pharma distribution.

📈 Shares currently trade at ~16.5x earnings, down from 20x earlier in the year.

✨ Analysts view the decline as an overreaction to a company with a strong track record.

📉 Cardinal Health's stock dropped 4.9% following its quarterly earnings report on Thursday.

✋ Analysts from the firm consider this decline an overreaction and state they would buy shares if allowed to trade.

⏱️ Jim Cramer mentioned Cardinal on CNBC TV, triggering a 72-hour trading restriction for his charitable trust which prevents an immediate purchase.

📈 The investment thesis is built on the company's track record of delivering double-digit earnings-per-share growth.

👵 A key positive driver is Cardinal's exposure to the secular trend of an aging U.S. population.

💊 The company has expanded into faster-growing, higher-margin areas such as specialty pharmaceutical distribution and management services organizations.

⚠️ Thursday's fiscal 2026 third-quarter report missed top-line expectations and included a $184 million goodwill impairment charge for its Navista and ION reporting units.

🗣️ CEO Jason Hollar confirmed that this impairment will not change their strategy regarding the MSO business line.

🎯 Management remains confident in growing adjusted earnings for fiscal 2027 within the long-term target range of 12% to 14%.

📊 Based on those estimates, Cardinal's shares are now trading at approximately 16.5 times next 12-month earnings, down from about 20x in early March.

🤝 Multiple Wall Street analysts, including Jefferies and Leerink Partners, have defended the stock and see no reason for the share price to be off without a massive rotation.

💧 Cardinal is described as a "good house in a bad neighborhood" within the healthcare sector, which currently has stocks that are out of favor.

🔄 When healthcare sentiment improves, analysts believe this well-positioned company will be among the first to be bought by investors.

Bullish Signals
  • Cardinal Health has a track record of delivering double-digit earnings-per-share growth, supported by the secular tailwind of an aging U.S. population.
  • The company has successfully expanded into faster-growing, higher-margin areas including specialty pharmaceutical distribution, at-home delivery, and management services organizations (MSOs).
  • CEO Jason Hollar reaffirmed confidence in growing adjusted earnings for fiscal 2027 within the long-term target range of 12% to 14%.
  • Valuation appears attractive as shares are trading at roughly 16.5 times the next 12 months' estimates, down from about 20x earnings when the stake was taken in early March.
  • Major Wall Street analysts support the positive outlook; Jefferies stated its thesis on Cardinal Health remains unchanged despite recent market overreaction.
  • Leerink Partners notes that momentum for Cardinal Health remains robust and that a pullback presents an opportunistic buying opportunity.
Risk Factors
  • Cardinal Health's stock price declined by 4.9% on Thursday following an earnings miss.
  • The company booked a $184 million goodwill impairment charge for its Navista and ION reporting units, creating market noise despite management's strategy remaining unchanged.
  • The article explicitly states that the top-line earnings report missed investor expectations.
  • Cardinal Health traded at roughly 16.5 times forward earnings in late September, a significant drop from the approximately 20 times multiple seen in early March when the author took a stake.
Bullish +75

CAH Gains on Q3 Earnings Beat, '26 EPS View Up Despite Revenue Miss

📈 Q3 adjusted EPS hit $3.17, beating estimates by 13.2% and rising 35% year-over-year.

💊 Pharma revenues and profits surged 11% and 18%, driving overall earnings growth.

⚠️ Tariff impacts hurt Medical Products profit, though operating income remains robust.

🔢 Guidance raised for fiscal 2026 EPS range to $10.70-$10.80.

💰 Cash reserves climbed to $3.94 billion while debt was reduced ahead of schedule.

📈 Cardinal Health reported third-quarter fiscal 2026 adjusted EPS of $3.17, beating the consensus estimate of $2.80 by 13.2%.

💰 Adjusted earnings per share represented a 35% year-over-year improvement in the bottom line.

💵 GAAP EPS for the quarter was $1.69 compared to $2.10 in the prior year period.

📉 Sales reached $60.94 billion, reflecting an 11% year-over-year increase but missing consensus estimates by 2.3%.

💊 Pharmaceutical revenues grew 11% to $56.11 billion driven by brand and specialty pharmaceutical sales growth.

🏭 Pharmaceutical profits totaled $784 million, a 18% increase from the previous year due to positive generics program performance.

📦 Global Medical Products and Distribution revenue remained flat at $3.15 billion, partially offsetting lower distribution volumes.

⚠️ The Global Medical Products segment profit dropped 36% to $25 million primarily due to adverse tariff impacts.

💉 At-Home Solutions and Nuclear segments within Global Medical grew significantly with sales up 31% and profit up 34%.

🔄 Gross margin increased to 4.1% of revenues, an improvement of almost 20 basis points year over year.

💸 Operating income decreased 30.3% to $509 million, while adjusted operating income rose 18.5% to $956 million.

🏦 The company ended the quarter with cash and equivalents of $3.94 billion, up from $2.78 billion in the prior quarter.

🚀 Cardinal Health raised its fiscal 2026 adjusted EPS guidance range to $10.70-$10.80 from $10.15-$10.35.

🛠️ The Pharmaceutical segment profit is now expected to grow 22-23% compared to the previous guidance of 20-22%.

💻 Shares of Cardinal Health rose 0.4% in pre-market trading despite a revenue miss but earnings beat.

🏥 Cardinal Health acquired Solaris Health to expand its urology presence, adding over 750 providers across 14 states.

⚡ The company expanded Actinium-225 production capabilities at its Nuclear and Precision Health Solutions Center for Theranostics Advancement.

💰 Management maintained a disciplined capital allocation strategy with debt reduced ahead of schedule and $1 billion in share repurchases.

Bullish Signals
  • EPS beat estimates by 13.2% with full-year improvement of 35%.
  • Pharmaceutical revenues grew 11% to $56.11 billion.
  • Pharmaceutical profit increased 18% to $784 million.
  • Nuclear segment sales surged 31% and profit up 34%.
  • Raised fiscal 2026 EPS guidance to $10.70-$10.80.
  • Cash grew significantly to $3.94 billion.
  • Reduced debt and returned $1.0B to shareholders.
  • Acquired Solaris Health adding 750 providers in 14 states.
  • Expanding Actinium-225 production for targeted therapies.
Risk Factors
  • GAAP EPS fell to $1.69 from $2.10 despite adjusted beat.
  • Revenues of $60.94B missed estimates by 2.3%.
  • Operating income dropped 30.3% year over year.
  • Medical segment profit down 36% due to tariff impacts.
  • Distribution expenses rose 17.3%, squeezing margins.
  • Analysts expect only 1-3% Medical growth vs other sectors.
  • Stock lost 1.3% YTD while S&P 500 gained 4.5%.
  • Debt cuts may limit future acquisitions or capital expenditure.
Bullish Signals
  • Cardinal Health reported Q3 adjusted EPS of $3.17, beating analyst estimates by 13.2% with a full-year improvement of 35% year over year.
  • Pharmaceutical revenues grew 11% to $56.11 billion driven by brand and specialty pharmaceutical sales growth from existing customers.
  • Pharmaceutical profit increased 18% to $784 million due to positive generics program performance and contributions from brand products.
  • Sales in the Nuclear and Precision Health Solutions segment surged 31% year over year, contributing to a 34% profit increase to $179 million.
  • The company raised its fiscal 2026 adjusted EPS guidance to $10.70-$10.80, representing 30-31% growth compared to the previous outlook.
  • Cardinal Health increased its Pharmaceutical segment profit guidance to 22-23% growth and Other segment profit guidance to 36-38% growth.
  • Cash and cash equivalents grew significantly to $3.94 billion from $2.78 billion, while net cash provided by operating activities jumped to $3.48 billion.
  • The company strengthened its balance sheet by reducing debt ahead of schedule and returning $1.0 billion to shareholders via share repurchases and dividends year to date.
  • The acquisition of Solaris Health added over 750 providers in 14 states, expanding The Specialty Alliance's reach to approximately 3,000 providers across 33 states.
  • Shares were up 0.4% in pre-market trading and underperformed the broader market declines, losing only 1.3% year-to-date versus the industry's 6.1% decline.
  • The company is expanding Actinium-225 production capabilities to support next-generation targeted therapies and data-driven healthcare solutions.
Risk Factors
  • While adjusted EPS beat estimates, GAAP EPS actually declined to $1.69 from $2.10 in the year-ago period, indicating underlying profitability headwinds.
  • Total revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%, revealing growth execution challenges despite top-line expansion efforts.
  • Operating income dropped 30.3% year over year to $509 million, a significant deterioration in core profitability that contrasts with adjusted earnings.
  • The Global Medical Products and Distribution segment reported a profit of only $25 million, down 36% from the prior year, primarily due to adverse net impacts from tariffs.
  • Distribution expenses increased 17.3% year over year to $1.54 billion, rising at a faster rate than revenues and squeezing margins.
  • Revenue growth estimates for the Medical segment are conservative, with analysts expecting only 1-3% growth compared to higher growth in other sectors.
  • The company faces competitive pressure as its stock has lost 1.3% year-to-date while the S&P 500 Index has gained 4.5%, underperforming the broader market.
  • Debt reduction and share repurchases, while positive, may limit future strategic acquisitions or capital expenditure if growth slows.
Somewhat Bullish +50

Cardinal Health (CAH) Q3 Earnings Beat Estimates

💰 Cardinal Health beat EPS estimates by 13.22% to reach $3.17 per share.

📉 Revenue missed consensus projections by 2.27% despite year-over-year growth.

⚠ Stock underperformed the S&P 500, gaining only 4.2% vs Cardinal's loss.

💰 Cardinal Health reported Q3 earnings of $3.17 per share, surpassing the Zacks Consensus Estimate of $2.80 and beating last year's $2.35 per share.

📈 The quarterly earnings surprise was +13.22%, following a previous quarter that also beat estimates by +10.04%.

✅ Over the trailing four quarters, Cardinal Health has exceeded consensus EPS estimates in four out of four instances.

📉 Revenue for the quarter ended March 2026 came in at $60.94 billion, which missed the Zacks Consensus Estimate by 2.27% despite rising from last year's $54.88 billion.

🔄 Cardinal has exceeded revenue estimates twice over the last four quarters.

⚠️ Analysts note that the sustainability of stock price movement will depend on management commentary during the earnings call.

📉 Cardinal Health shares have underperformed, losing about 1.3% year-to-date compared to the S&P 500's 4.2% gain.

📊 The Zacks Rank for Cardinal is #2 (Buy), driven by favorable estimate revisions and a strong correlation between these trends and near-term stock movements.

🔮 Current consensus estimates project $2.34 EPS and $67.23 billion revenue for the coming quarter, alongside $10.32 EPS and $259.11 billion revenue for the fiscal year.

🏥 Cardinal Health belongs to the Zacks Medical - Dental Supplies industry, which is currently ranked in the top 22% of all industries.

🆚 Peer company Lifevantage (LFVN) has not yet reported its Q3 results, which are expected on May 6 with estimated earnings of $0.16 per share.

⬇️ For Lifevantage, analysts expect revenues of $47.82 million, representing an 18.2% year-over-year decline.

Bullish Signals
  • Cardinal Health beat estimates with $3.17 EPS (+13.22%),.
  • Consistently exceeded consensus in 4/4 last quarters.
  • Holds Zacks Rank #2 Buy rating.
  • In top 22% high-performing industry sector.
  • Y/Y earnings grew from $2.35 to $3.17.
Risk Factors
  • Cardinal Health revenue missed analyst estimates despite beating earnings.
  • Stock lost 1.3% this year, underperforming the S&P 500's 4.2% gain.
  • Future performance hinges on management commentary rather than current results.
  • Peer Lifevantage faces a significant -38.5% drop in expected earnings.
Bullish Signals
  • Cardinal Health reported quarterly earnings of $3.17 per share, surpassing the Zacks Consensus Estimate of $2.8 per share with a positive surprise of +13.22%.
  • The company has exceeded consensus EPS estimates in four out of the last four quarters, demonstrating consistent performance strength.
  • Cardinal currently holds a Zacks Rank #2 (Buy), indicating strong potential to outperform the market in the near future based on favorable earnings estimate revisions.
  • The Medical - Dental Supplies industry ranks in the top 22% of all Zacks industries, positioning Cardinal within a high-performing sector that historically outperforms the bottom half by more than 2 to 1.
  • Year-over-year earnings increased from $2.35 per share to the current $3.17 per share, reflecting robust business growth after adjusting for non-recurring items.
Risk Factors
  • Cardinal Health's quarterly revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.27%, indicating a downward revision in analyst expectations despite an earnings beat.
  • The company's stock price has lost approximately 1.3% since the beginning of the year, significantly underperforming the S&P 500's gain of 4.2% during the same period.
  • Investors face uncertainty regarding future stock performance as the sustainability of recent price movements depends heavily on management's upcoming commentary rather than immediate financial results.
  • A peer competitor in the same industry, Lifevantage (LFVN), reports a significant decline in expected earnings with an EPS of $0.16 representing a -38.5% year-over-year change.
Bearish -50

Cardinal Health is getting pummeled on mixed results — here's our plan for stock

📉 Revenue missed expectations at $60.94B despite an 11% year-over-year growth.

💰 Adjusted earnings beat estimates significantly at $3.17 per share.

⚠️ Tariffs caused profit drops in distribution while GLP-1 demand surged in pharma.

🔼 Analysts raised price targets and maintained Buy ratings despite mixed results.

📉 Cardinal Health shares are dropping after reporting mixed quarterly results that disappointed investors on revenue but beat earnings estimates.

💰 Revenue for the quarter ended March 31 grew 11% year-over-year to $60.94 billion, missing analyst expectations of $61.7 billion according to LSEG.

🧮 Adjusted earnings per share came in at $3.17, which beat the consensus estimate of $2.79 compiled by LSEG.

⚠️ Jim Cramer described the company's performance as "Good, not great" during his Morning Meeting segment on Thursday.

📉 While overall profitability remained strong and free cash flow tripled Street estimates, sales missed targets across all three operating segments.

🏭 The Global Medical Products and Distribution segment faced significant challenges due to lower distribution volumes and the negative impact of tariffs.

💊 Revenue in the Pharmaceutical and Specialty Solutions segment rose 11% to $56.2 billion, driven by strong demand for GLP-1 weight-loss drugs which grew over 30%.

📉 The Other segment saw a 31% revenue increase to $1.7 billion, though it still fell short of Wall Street expectations.

⚖️ In Global Medical Products and Distribution, profits plummeted by 35% year-over-year primarily due to tariff-related costs offsetting revenue gains from brand products.

🔼 Management raised its full-year earnings outlook, but noted that only 13 cents of the $0.50 increase stems from operational improvements rather than taxes or expenses.

📉 The stock is currently trading around $190 with a forward P/E ratio of 16x fiscal year 2027 estimates, which is at the lower end of its valuation range over the past year.

⚠️ Analysts are maintaining their "Buy" rating but trimming the price target from $260 to $225 while waiting for more clarity on the situation.

📉 Technical indicators show the stock has entered oversold territory with a Relative Strength Index (RSI) cross, suggesting significant pessimism is baked into the price.

🛑 The stock is hovering near its 200-day moving average support level after being down more than 6%, making investors cautious about rushing in at the dip.

🏢 CEO Jason Hollar emphasized that cost optimization initiatives are delivering results while the company navigates a dynamic and challenging tariff environment.

Bullish Signals
  • Revenue for the three months ended March 31 increased 11% year over year to $60.94 billion, demonstrating solid top-line growth despite missing high expectations.
  • Adjusted earnings per share (EPS) came in at $3.17, significantly beating the consensus estimate of $2.79 by approximately 14%.
  • Free cash flow was three times the Street's consensus estimate, indicating strong operational efficiency and cash generation capabilities.
  • Management raised its full-year earnings outlook, signaling confidence in the company's long-term trajectory despite recent mixed results.
  • Revenue in the Pharmaceutical and Specialty Solutions segment increased 11% year over year to $56.2 billion, driven by strong demand for brand and specialty pharmaceuticals.
  • The company reported a more than 30% revenue growth for obesity and weight-loss medicines (GLP-1 drugs), contributing significantly to segment revenue expansion.
  • In the Other segment, revenue surged 31% year over year to $1.7 billion, driven by growth across Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics.
  • CEO Jason Hollar highlighted tangible results from simplification and cost optimization initiatives, along with notable strength in the Cardinal Health brand product portfolio.
Risk Factors
  • Revenue missed expectations by $666 million for the quarter, with total revenue at $60.94 billion versus the consensus estimate of $61.7 billion.
  • The Pharmaceutical and Specialty Solutions segment revenue shorted estimates by $1.36 billion, arriving at $56.2 billion against an expected $57.56 billion.
  • Global Medical Products and Distribution sales were held back by lower distribution volumes, resulting in revenue missing expectations despite offsetting brand growth.
  • Segment profit for Global Medical Products and Distribution plummeted 35% year over year to a low of $3.25 billion, largely due to negative impact from tariffs.
  • The stock is down more than 6% from its recent highs and trading around the critical 200-day moving average support level.
  • Analyst price target has been trimmed significantly from $260 to $225 following the mixed earnings report and sell-off.
  • Only 13 cents of the 50-cent full-year earnings midpoint increase is attributable to operational performance, with the remainder driven by non-operational factors like taxes and share repurchases.
  • The stock is trading at 16 times fiscal year 2027 estimates, which is near the lowest valuation level seen since October of the previous year.
Somewhat Bullish +50

Cardinal Health reports Q3 results, raises outlook

💰 Revenues jumped 11% to $6.09B, with Pharma driving the majority of growth.

⚠ GAAP earnings fell 30% after a $184M goodwill impairment charge in Navista & ION.

📈 Non-GAAP earnings rose 18% as tax benefits offset higher interest expenses.

🏆 AmerisourceBergen, AbbVie, and Cardinal Health received perfect scores in Barron's 500 rankings.

💰 Cardinal Health reported Q3 fiscal year 2026 revenues of $6.09 billion (11% increase YoY).

⚠️ GAAP operating earnings fell 30% to $509 million due to a $184 million goodwill impairment in Navista & ION units.

📊 Non-GAAP operating earnings rose 18% to $956 million as lower tax rates and share counts offset higher interest expenses.

🗣️ CEO Jason Hollar praised the quarter's resilience, stating strong performance in pharma and specialty solutions positions them for long-term value.

💊 Pharmaceutical and specialty solutions revenue grew 11% to $5.61 billion driven by brand and specialty sales from existing customers.

📈 Profits in the pharmaceutical and specialty segment increased 18% to $784 million thanks to positive generics program performance.

🏥 Global medical products and distribution revenue remained flat YoY as lower volumes were offset by Cardinal Health's own brand growth.

📉 Medical products segment profit dropped 36% to $25 million, primarily due to the adverse net impact of tariffs.

🛠️ Other segment revenue jumped 31% to $1.7 billion, fueled by growth in at-home solutions, nuclear/precision health, and logistics.

💹 The "Other" segment profit climbed 34% to $179 million driven by acquisitions like Advanced Diabetes Supply and OptiFreight Logistics.

🏆 AmerisourceBergen, AbbVie, and Cardinal Health earned perfect scores in the Barron's 500 list of largest US/Canadian publicly traded companies.

📐 The top three companies received perfect 4.0 grade point averages based on return on investment and sales growth metrics.

Bullish Signals
  • Third quarter FY26 revenues hit $60.9 billion, up 11%.
  • Non-GAAP earnings rose 18% to $956 million.
  • Diluted EPS surged 35% to $3.17.
  • Pharma segment revenue grew 11% to $56.1 billion.
  • Pharma profit increased 18% to $784 million.
  • 'Other' segment revenue jumped 31% to $1.7 billion.
  • 'Other' segment profit rose 34% to $179 million.
  • FY26 outlook raised on strong operating performance.
  • Company earned perfect scores in Barron's 500 list.
Risk Factors
  • GAAP operating earnings fell 30% to $509 million.
  • $184 million goodwill impairment hit Navista & ION units.
  • Global medical revenue remained flat amid lower volumes.
  • Medical profit dropped 36% due to tariffs' impact.
  • Earnings guidance depends on momentum vulnerable to high interest.
Bullish Signals
  • Cardinal Health reported third quarter fiscal year 2026 revenues of $60.9 billion, representing an increase of 11% from the prior year.
  • Non-GAAP operating earnings increased 18% to $956 million, with diluted EPS rising 35% to $3.17.
  • The pharmaceutical and specialty solutions segment showed strong growth, with revenue increasing 11% to $56.1 billion.
  • Profit within the pharmaceutical and specialty solutions segment increased 18% to $784 million, driven by positive generics program performance.
  • Revenue in the 'other' segment surged 31% to $1.7 billion, driven by growth in at-Home solutions, nuclear and precision health, and OptiFreight Logistics.
  • Profit for the 'other' segment increased 34% to $179 million, further validating strong performance across its diverse portfolio.
  • CEO Jason Hollar stated that an excellent third quarter extends fiscal 2026 momentum due to the durability and resilience of the business.
  • Management raised their fiscal 2026 outlook based on strong operating performance and confidence in long-term value creation.
  • The company received perfect scores in Barron's 500 list, earning a 4.0 grade point average alongside major peers like AmerisourceBergen and AbbVie.
Risk Factors
  • Third quarter GAAP operating earnings decreased 30% to $509 million, with GAAP diluted EPS dropping 20% to $1.69.
  • The company recorded a significant $184 million pre-tax goodwill impairment in its Navista & ION reporting unit due to changes in the risk profile of business plans and an increased discount rate.
  • Third quarter revenue for the global medical products and distribution segment remained flat, reflecting lower distribution volumes.
  • Global medical products and distribution segment profit decreased 36% to $25 million, primarily driven by the adverse net impact of tariffs.
  • The overall earnings guidance raise relies on momentum that could be offset by high interest and other expenses noted in the non-GAAP calculations.
Neutral 0

Cardinal: Fiscal Q3 Earnings Snapshot

💰 Q3 net income hit $399M, exceeding Wall Street expectations.

📈 Adjusted earnings per share reached $3.17 versus the $2.80 consensus.

📉 Revenue fell short at $60.94B against a $62.35B forecast.

💰 Cardinal Health reported fiscal Q3 net income of $399 million, beating Wall Street expectations.

📈 Adjusted earnings came in at $3.17 per share compared to an analyst consensus of $2.80.

⚠️ Revenue for the quarter reached $60.94 billion, falling short of the estimated $62.35 billion forecast.

💼 Profit on a per-share basis was reported at $1.69 following the standard accounting adjustments.

📅 The company projects full-year earnings will range between $10.70 and $10.80 per share.

📉 Cardinal shares have declined over 1% since the start of the year despite a gain of 45% in the last 12 months.

📊 The broader S&P 500 index has risen by 4%, highlighting a performance divergence for the stock.

📋 These financial results were provided by Cardinal Health Inc., a Dublin, Ohio-based prescription drug distributor.

Bullish Signals
  • Shares gained 45% last 12 months.
  • Demonstrates strong resilience despite revenue miss.
Risk Factors
  • Revenue of $60.94B missed analyst expectations of $62.35B.
  • Cardinal shares fell over 1% YTD, trailing S&P 500's 4% gain.
Bullish Signals
  • Despite a slight miss in revenue, Cardinal shares have gained 45% over the last 12 months, demonstrating resilience and long-term value creation for shareholders.
Risk Factors
  • Revenue of $60.94 billion missed Street forecasts, with analysts surveyed by Zacks expecting $62.35 billion.
  • Cardinal shares have dropped slightly more than 1% since the beginning of the year, trailing the S&P's 500 index which has climbed 4% during the same period.